ESSA Pharma Inc. (EPIX)
ESSA Pharma Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Vancouver, BC, CA. The stock last traded at $0.20, down 1.85% on the session, giving a market capitalisation of $9.5M. On trailing twelve-month figures it carries a trailing P/E of -0.87, a net margin of 0.0%. Its beta of 1.53 implies it has historically moved more than the broad market.
ESSA Pharma Inc. (EPIX) functions as a clinical-stage pharmaceutical firm, concentrating its efforts on developing innovative and exclusive therapies designed to combat prostate cancer. The company's primary drug candidate is EPI-7386, an oral treatment presently undergoing Phase I clinical trials. This investigational compound is intended for individuals suffering from metastatic castration-resistant prostate cancer. Furthermore, ESSA Pharma has established collaborative partnerships with organizations including Caris Life Sciences, Inc., Bayer Consumer Care AG, Janssen Research & Development, LLC, and Astellas Pharma Inc. Founded in 2009, the company's corporate offices are located in Vancouver, Canada.
ESSA Pharma Inc. is most often compared with the following Healthcare names: